Sangamo Therapeutics, Inc.
7000 Marina Blvd
Brisbane
CA
94005
United States
Tel: (510) 970-6000
Website: https://www.sangamo.com/
Email: hr@sangamo.com
About Sangamo Therapeutics, Inc.
Sangamo Therapeutics is a genomic medicine company building value with cutting-edge work across four distinct but complementary technology platforms – gene therapy, cell therapy, in vivo genome editing, and in vivo genome regulation. At Sangamo, we are passionate in developing genomic medicines to transform the lives of patients with serious diseases. We transform lives by building a robust, sustainable, differentiated, innovative, and high value genomic medicine pipeline that addresses patients with life-limiting conditions. Sangamo takes pride in being the first to edit endogenous human genes, first to treat patients with gene edited T cells, and first to treat patients with in vivo genome editing. Our top priority is to meet the needs of patients with commitment and compassion. Along with our commitment to science and to our patients, we also endeavor to create an inclusive environment that promotes and values diversity. Sangamo is a company where individuals can flourish, grow and develop their expertise.
We are seeking top talent to join our mission. Let’s build a better future together.
Stock Symbol: SGMO
634 articles about Sangamo Therapeutics, Inc.
-
Sangamo BioSciences, Inc. (JOBS) Drug Helps Muscle in 1/3 of ALS Patients
12/9/2009
-
Sangamo BioSciences, Inc. Reports Third Quarter 2009 Financial Results
11/5/2009
-
Sangamo BioSciences, Inc. Announces Presentation at Merriman Curhan Ford & Co.'s Investor Summit 2009
11/4/2009
-
Sangamo BioSciences, Inc. Announces Third Quarter 2009 Conference Call and Webcast
10/29/2009
-
Sangamo BioSciences, Inc. Announces Presentation of Top-Line Statistically Significant Phase 2 Data in Diabetic Neuropathy at Society for Neuroscience Meeting Improvement in Intraepidermal Nerve Fiber Density Demonstrates Neuroregenerative Mechanistic Pr
10/21/2009
-
Sangamo BioSciences, Inc. Announces Closing of Common Stock Offering
10/13/2009
-
Sangamo BioSciences, Inc. Announces Pricing of Public Offering of Common Stock
10/7/2009
-
Sangamo BioSciences, Inc. (JOBS) Lands $20 Million in Expanded Sigma-Aldrich Corporation Deal
10/5/2009
-
Sangamo BioSciences, Inc. Announces Research Collaboration With University of California, Los Angeles (UCLA) in Human Stem Cells Selected to Receive Clinical Research Award
10/1/2009
-
Sangamo BioSciences, Inc. Announces Presentation at the JMP Securities Healthcare Conference
9/29/2009
-
Sangamo BioSciences, Inc. Announces Presentation at the UBS Global Life Sciences Conference
9/17/2009
-
Sangamo BioSciences, Inc.'s Zinc Finger Nuclease Technology Used to Efficiently Modify Human Stem Cells
9/8/2009
-
Sangamo BioSciences, Inc. Reports Second Quarter 2009 Financial Results
7/30/2009
-
Medical College of Wisconsin, Sangamo BioSciences, Inc., Sigma-Aldrich Corporation, Open Monoclonal Technology, Inc., And INSERM Researchers Create First Targeted Knockout Rats Using Zinc Finger Nuclease Technology
7/27/2009
-
Sangamo BioSciences, Inc. Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech, Inc.
6/29/2009
-
Sangamo BioSciences, Inc. Presents Positive Phase 2 ZFP Therapeutic Data at ADA 2009
6/8/2009
-
Sangamo BioSciences, Inc. Announces Presentation at the Needham Life Sciences Conference
6/4/2009
-
Sangamo BioSciences, Inc. Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research
5/4/2009
-
Sangamo BioSciences, Inc. Reports First Quarter 2009 Financial Results
4/30/2009
-
Sangamo BioSciences, Inc. Announces Publication in Nature of the Use of Zinc Finger Nucleases to Accelerate Precision Trait Stacking in Commercial Crop Species
4/29/2009